MORGAN STANLEY PLC/PUT/ELI LILLY & CO/600/0.01/16.01.26 | Real-time Bid/Ask 03:40:15 2024-06-27 EDT | ||
| 0.25 EUR / 0.27 EUR | 0.00% |
|
| 1 month | -25.71% | ||
| 3 months | -43.48% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-26 | 0.26 | +4.00% |
| 24-06-25 | 0.25 | -3.85% |
| 24-06-24 | 0.26 | -3.70% |
| 24-06-21 | 0.27 | 0.00% |
| 24-06-20 | 0.27 | +3.85% |
Delayed Quote Börse Stuttgart
Last update June 26, 2024 at 12:22 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | Morgan Stanley |
| WKN | ME0HJW |
| ISIN | DE000ME0HJW9 |
| Date issued | 2023-09-11 |
| Strike | 600 $ |
| Maturity | 2026-01-16 (569 Days) |
| Parity | 100 : 1 |
| Emission price | 0.99 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.18 € |
|---|---|
| Lowest since issue | 0.24 € |
| Spread | 0.02 € |
| Spread % | 7.41% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
901.3
USD
Average target price
860.5
USD
Spread / Average Target
-4.52%
- Stock Market
- Warrants
- Warrant
